Literature DB >> 17355243

At diabetes-like concentration, glucose down-regulates the placental serotonin transport system in a cell-cycle-dependent manner.

R Unal1, B A Ahmed, B C Jeffus, J T Harney, C S Lyle, Y-K Wu, T C Chambers, E A Reece, F Kilic.   

Abstract

Serotonin [5-hydroxytryptamine (5HT)] is a vasoconstrictor that also acts as a developmental signal early in embryogenesis. The 5HT transporter (SERT) on the membranes of the placental trophoblast cells controls 5HT levels in the maternal bloodstream to maintain stable transplacental blood flow and simultaneously provide 5HT to the embryo. The 5HT uptake rate of placental SERT is important for both the mother and the developing embryo. The impact of glucose on the placental SERT system during diabetic pregnancy is not known. The present in vitro study investigated this important issue in human placental choriocarcinoma (JAR) cells that were cultured for 24-96 h in a medium containing either 5.5 (physiologic concentration) or 25 mmol/L D-glucose (diabetic-like concentration). The 5HT uptake rates of the cultured cells were not altered at exogenous D-glucose concentrations in the range of 5.5-15 mmol/L, but were decreased significantly at a diabetic-like concentration (>or=25 mmol/L). To understand better the role of glucose on the placental 5HT system, we first characterized SERT in JAR cells at different cell-cycle phases and then determined the expression levels of SERT on the plasma membrane and in the intracellular pools of JAR cells at the late-S and G2 phases, where the uptake rates were decreased 73% under diabetic-like glucose concentrations. Finally, the importance of self-association of SERT molecules was examined. In JAR cells co-expressing Flag- and myc-tagged SERT, myc-antibody precipitated 70% of Flag-SERT, indicating that a large percentage of SERT proteins exist as oligomers in situ. Under diabetic conditions, myc-antibody no longer precipitated Flag-SERT, suggesting a disruption in the aggregation of SERT molecules. Therefore, we propose that under uncontrolled diabetic conditions, glucose down-regulates 5HT uptake rates of placental SERT by interfering with its functional expression in a cell-cycle-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17355243      PMCID: PMC3042026          DOI: 10.1111/j.1471-4159.2007.04469.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  37 in total

1.  The ETS domain factor Pet-1 is an early and precise marker of central serotonin neurons and interacts with a conserved element in serotonergic genes.

Authors:  T Hendricks; N Francis; D Fyodorov; E S Deneris
Journal:  J Neurosci       Date:  1999-12-01       Impact factor: 6.167

2.  Hyperglycaemia in vitro alters the proliferation and mitochondrial activity of the choriocarcinoma cell lines BeWo, JAR and JEG-3 as models for human first-trimester trophoblast.

Authors:  U Weiss; M Cervar; P Puerstner; O Schmut; J Haas; R Mauschitz; G Arikan; G Desoye
Journal:  Diabetologia       Date:  2001-02       Impact factor: 10.122

3.  Biochemistry and molecular cell biology of diabetic complications.

Authors:  M Brownlee
Journal:  Nature       Date:  2001-12-13       Impact factor: 49.962

4.  Pet-1 ETS gene plays a critical role in 5-HT neuron development and is required for normal anxiety-like and aggressive behavior.

Authors:  Timothy J Hendricks; Dmitry V Fyodorov; Lauren J Wegman; Nadia B Lelutiu; Elizabeth A Pehek; Bryan Yamamoto; Jerry Silver; Edwin J Weeber; J David Sweatt; Evan S Deneris
Journal:  Neuron       Date:  2003-01-23       Impact factor: 17.173

5.  Excessive activation of serotonin (5-HT) 1B receptors disrupts the formation of sensory maps in monoamine oxidase a and 5-ht transporter knock-out mice.

Authors:  N Salichon; P Gaspar; A L Upton; S Picaud; N Hanoun; M Hamon; E De Maeyer ; D L Murphy; R Mossner; K P Lesch; R Hen; I Seif
Journal:  J Neurosci       Date:  2001-02-01       Impact factor: 6.167

6.  Serotonin transporter function is an early step in left-right patterning in chick and frog embryos.

Authors:  Takahiro Fukumoto; Randy Blakely; Michael Levin
Journal:  Dev Neurosci       Date:  2005       Impact factor: 2.984

7.  Oligomerization of the human serotonin transporter and of the rat GABA transporter 1 visualized by fluorescence resonance energy transfer microscopy in living cells.

Authors:  J A Schmid; P Scholze; O Kudlacek; M Freissmuth; E A Singer; H H Sitte
Journal:  J Biol Chem       Date:  2000-11-08       Impact factor: 5.157

8.  A human serotonin transporter mutation causes constitutive activation of transport activity.

Authors:  Fusun Kilic; Dennis L Murphy; Gary Rudnick
Journal:  Mol Pharmacol       Date:  2003-08       Impact factor: 4.436

9.  Functional consequences of homo- but not hetero-oligomerization between transporters for the biogenic amine neurotransmitters.

Authors:  A M Kocabas; G Rudnick; F Kilic
Journal:  J Neurochem       Date:  2003-06       Impact factor: 5.372

10.  Oligomerization of serotonin transporter and its functional consequences.

Authors:  F Kilic; G Rudnick
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more
  3 in total

1.  GDM-associated insulin deficiency hinders the dissociation of SERT from ERp44 and down-regulates placental 5-HT uptake.

Authors:  Yicong Li; Coedy Hadden; Preeti Singh; Charles P Mercado; Pamela Murphy; Nafisa K Dajani; Curtis L Lowery; Drucilla J Roberts; Luc Maroteaux; Fusun Kilic
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

Review 2.  Drug transporters in the human blood-placental barrier.

Authors:  Kirsi Vähäkangas; Päivi Myllynen
Journal:  Br J Pharmacol       Date:  2009-09-25       Impact factor: 8.739

3.  Epigenetic adaptation of the placental serotonin transporter gene (SLC6A4) to gestational diabetes mellitus.

Authors:  Sofia Blazevic; Marina Horvaticek; Maja Kesic; Peter Zill; Dubravka Hranilovic; Marina Ivanisevic; Gernot Desoye; Jasminka Stefulj
Journal:  PLoS One       Date:  2017-06-26       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.